Banca de QUALIFICAÇÃO: LUCAS MELO DA COSTA

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : LUCAS MELO DA COSTA
DATE: 10/07/2025
TIME: 14:30
LOCAL: Sala do PPGCO situada no setor de Endodontia/DOD
TITLE:

TARGETING BCL-2 IN ORAL SQUAMOUS CELL CARCINOMA CELL LINES: IN VITRO EFFICACY OF VENETOCLAX (ABT-199) ALONE AND IN COMBINATION WITH 5-FLUOROURACIL (5-FU)

KEY WORDS:

Oral squamous cell carcinoma; Apoptosis; drug resistance neoplasm; BCL-2; BH3 Interacting Domain Death Agonist Protein

PAGES: 35
BIG AREA: Ciências da Saúde
AREA: Odontologia
SUBÁREA: Clínica Odontológica
SUMMARY:

Introduction: Oral squamous cell carcinoma (OSCC) is the most prevalent malignant neoplasm of the oral cavity and is associated with high morbidity and mortality rates, particularly in cases diagnosed at advanced stages. Resistance to conventional therapies, such as 5-fluorouracil (5-FU)-based chemotherapy, remains a major therapeutic challenge, often attributed to the overexpression of anti-apoptotic proteins such as BCL-2. In this context, Venetoclax (ABT-199), a selective BCL-2 inhibitor, has demonstrated promising activity in various malignancies; however, its efficacy in OSCC remains poorly explored. Objectives: This study aims to investigate, in vitro, the therapeutic potential of ABT-199, both as a monotherapy and in combination with 5-FU, in OSCC cell lines. Materials and Methods: This is a laboratory-based experimental study. OSCC cell lines will be screened for BCL-2 expression via Western blotting and RT-qPCR to identify the most suitable model. Subsequently, cells will be treated with varying concentrations of ABT-199 and 5-FU, administered alone and in combination. Cellular proliferation (BrdU assay), migration (wound healing assay), and invasion (Transwell assay) will be assessed to evaluate the impact of the treatments on key aspects of tumor behavior. The findings of this study are expected to contribute to the preclinical evidence regarding the applicability of ABT-199 as a targeted therapy for OSCC, supporting future combined therapeutic strategies.

COMMITTEE MEMBERS:
Presidente - 1298808 - MARCIA CRISTINA DA COSTA MIGUEL
Interno - 2220417 - CARLOS AUGUSTO GALVAO BARBOZA
Interna - 2492713 - ERICKA JANINE DANTAS DA SILVEIRA